These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1546 related articles for article (PubMed ID: 21459215)

  • 1. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.
    Ishibashi T; Li X; Koh A; Lai TY; Lee FL; Lee WK; Ma Z; Ohji M; Tan N; Cha SB; Shamsazar J; Yau CL;
    Ophthalmology; 2015 Jul; 122(7):1402-15. PubMed ID: 25983216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
    Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F
    Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
    Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
    JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
    Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
    Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    ; Elman MJ; Aiello LP; Beck RW; Bressler NM; Bressler SB; Edwards AR; Ferris FL; Friedman SM; Glassman AR; Miller KM; Scott IU; Stockdale CR; Sun JK
    Ophthalmology; 2010 Jun; 117(6):1064-1077.e35. PubMed ID: 20427088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
    Schmidt-Erfurth U; Lang GE; Holz FG; Schlingemann RO; Lanzetta P; Massin P; Gerstner O; Bouazza AS; Shen H; Osborne A; Mitchell P;
    Ophthalmology; 2014 May; 121(5):1045-53. PubMed ID: 24491642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
    Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Elman MJ; Bressler NM; Qin H; Beck RW; Ferris FL; Friedman SM; Glassman AR; Scott IU; Stockdale CR; Sun JK;
    Ophthalmology; 2011 Apr; 118(4):609-14. PubMed ID: 21459214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
    Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.
    Bressler NM; Varma R; Mitchell P; Suñer IJ; Dolan C; Ward J; Ferreira A; Ehrlich JS; Turpcu A
    JAMA Ophthalmol; 2016 Feb; 134(2):160-6. PubMed ID: 26584450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.
    ; Elman MJ; Qin H; Aiello LP; Beck RW; Bressler NM; Ferris FL; Glassman AR; Maturi RK; Melia M
    Ophthalmology; 2012 Nov; 119(11):2312-8. PubMed ID: 22999634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
    Do DV; Nguyen QD; Khwaja AA; Channa R; Sepah YJ; Sophie R; Hafiz G; Campochiaro PA;
    JAMA Ophthalmol; 2013 Feb; 131(2):139-45. PubMed ID: 23544200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.
    Lang GE; Berta A; Eldem BM; Simader C; Sharp D; Holz FG; Sutter F; Gerstner O; Mitchell P;
    Ophthalmology; 2013 Oct; 120(10):2004-12. PubMed ID: 23725735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
    Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
    Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
    Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
    Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
    Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.